OPKO Health Files 13D/A Amendment for GeneDx Holdings

TL;DR

OPKO Health updated its 13D filing on GeneDx. Ownership details changed.

AI Summary

OPKO Health, Inc. has filed an amendment to its Schedule 13D, indicating a change in its beneficial ownership of GeneDx Holdings Corp. as of August 23, 2024. The filing details OPKO Health's holdings and intentions regarding GeneDx.

Why It Matters

This filing provides insight into the ownership structure and potential strategic moves of OPKO Health concerning GeneDx Holdings, which could impact GeneDx's stock and future operations.

Risk Assessment

Risk Level: medium — Changes in beneficial ownership filings can signal shifts in control or strategy, potentially affecting stock price and requiring further investigation.

Key Players & Entities

• OPKO HEALTH, INC. (company) — Filing entity
• GeneDx Holdings Corp. (company) — Subject company
• 20240823 (date) — Filing date

FAQ

Key Financial Figures

• $0.0001 — suer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securiti
• $33.00 — the open market at prices ranging from $33.00 to $35.9175 per share for an aggregate
• $35.9175 — market at prices ranging from $33.00 to $35.9175 per share for an aggregate sale price o
• $10,632,473 — n aggregate sale price of approximately $10,632,473. ITEM 5. Interest in Securities of
• $26.4607 — the open market at prices ranging from $26.4607 to $35.9175 per share for an aggregate
• $34,703,115 — n aggregate sale price of approximately $34,703,115. Sales of GeneDx Common Stock prior to

Filing Documents

• opk20240821c_sc13da.htm (SC 13D/A) — 81KB
• 0001437749-24-027693.txt ( ) — 83KB

is amended by adding the following paragraph to the end of the item

Item 4 is amended by adding the following paragraph to the end of the item: In a series of transactions between August 13, 2024 and August 23, 2024, OPKO sold a total of 309,637 shares of GeneDx Common Stock on the open market at prices ranging from $33.00 to $35.9175 per share for an aggregate sale price of approximately $10,632,473. ITEM 5. Interest in Securities of the Issuer.

is deleted in its entirety and replaced with the following text

Item 5 is deleted in its entirety and replaced with the following text: (a) The Company's beneficial ownership of GeneDx Common Stock is as set forth in the table below: Name and Title of Beneficial Owner Number of Outstanding Shares Beneficially Owned Percentage of Outstanding Common Shares (1) OPKO Health, Inc. 2,502,146 9.29% ______________ (1) Based on 26,935,897 shares of GeneDx Common Stock of the Issuer outstanding on July 22, 2024, as set forth in the Issuer's Form 10-Q filed with the SEC on July 30, 2024. (b) Items 7-10, inclusive, set forth on the cover page to this Amendment are hereby incorporated by reference in this Item 5. (c) In the last 60 days prior to the filing of this Amendment No. 6, OPKO sold a total of 1,056,457 shares of GeneDx Common Stock on the open market at prices ranging from $26.4607 to $35.9175 per share for an aggregate sale price of approximately $34,703,115. Sales of GeneDx Common Stock prior to August 13, 2024 were previously reported in Amendment No. 4 and Amendment No. 5. The following table sets forth the information with regard to GeneDx Common Stock sold by OPKO on the open market in the last 60 days. Date Shares of Common Stock Aggregate Purchase Price Weighted Price Per Share 7/1/24 50,000 $ 1,331,669 $ 26.6340 7/2/24 25,000 $ 728,095 $ 29.1238 7/3/24 14,082 $ 397,491 $ 28.2269 7/5/24 36,118 $ 1,020,015 $ 28.2412 7/17/24 25,000 $ 823,187 $ 32.9275 7/19/24 25,000 $ 807,250 $ 32.29 7/22/24 50,000 $ 1,630,422 $ 32.6088 7/23/24 75,000 $ 2,509,248 $ 33.4566 7/24/24 75,000 $ 2,529,102 $ 33.7214 7/26/24 60,000 $ 2,031,255 $ 33.8543 CUSIP No. 81663L200 Schedule 13D PAGE 4 of 5 7/29/24 50,000 $ 1,692,890 $ 33.8578 7/31/24 88,839 $ 2,976,350 $ 33.5027 8/6/24 12,994 $ 381,427 $ 29.3541 8/8/24 100,000 $ 3.182.380 $ 31.8238 8/12/24 59,787 $ 2,029,811 $ 33.9507

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. OPKO Health, Inc. Dated: August 23, 2024 By: /s/ Steven D. Rubin Name: Steven D. Rubin Title: Executive Vice President - Administration

View Full Filing

View this SC 13D/A filing on SEC EDGAR